We risk losing much more eager to respond countries

With the advent of telehealth, the promise of personalized medicine for patients, or the development of nanotechnology research, we are at the dawn of changes in the field of health. And few are those who see - on the merits - mutations at work. As a result of new information and communication technologies, the landscape of health in ten years will be very different from what we know today. And in this global reconfiguration is part the need to develop new products and services to meet new needs related to the ageing of the population and the growth of the care home. If the future is never written, the potential of development for the medical industry appears as a certainty. The countries that will be able to establish order of battle quickly and develop local skills will have a leading role. In this competition, the France has all the advantages for itself.

With a very rich medical technology industry, the France is a land of medical innovation. It has always been, and there it remains. In terms of stability and employment, the economic crisis also revealed the health industries, for countries that had the legitimacy, more a chance that a charge. With a trade surplus heavily, health companies constitute a value deposit it back up, with an increase in employment. Medical training is among the best in France, which is another asset. Today, the medical device lives independently, but it will also, in the future, connected to the drug and the diagnosis. To identify these new growth niche, many efforts have been made upstream in order to facilitate the dynamics of the networks of excellence. It has sought to bring together the academic research of the industry, but also the start-up - often from this academic research - industry to which they provide answers. The meeting precedes the idea and this reality is reflected in competitiveness clusters as Lyon Biopole. Lyon in Toulouse, Nantes and Strasbourg, we have world-class skills equivalent to what can be found in the United States, England, in Singapore regions... An advantage too often overlooked and yet pointed out by the President of the Republic, on October 26, strategic Council of health industries. It thus highlighted the attractiveness of the France as it was seen across the Atlantic, with competitiveness strengthened in Europe, including by the research tax credit.

These remarks were encouraging. Must not lose sight of an inconsistency, in France, penalizes our image and our performance. While it is true that, as industrial facilities to invest in innovation, our scope of action regarding the broadcast of these innovations is largely limited. Therefore that it is to validate and enhance these innovations to the administration, it is still very long.

This slow is probably due to a desire to minimize the cost of health - what can understand - but this is not the right way to do. We risk losing much more eager to respond countries. If it is important to identify innovations upstream, it is also vital to find them downstream so that they develop and are produced in our territory. The emergence of new medical needs, it is high time now to establish a mesh of our skills in research and technology, to ensure that these streams are perennial and have the means to exist and progress. This is the issue of the States General of the industry, whose decisions will shape the next 10 years.

To the current mutations, we, together, thinking about a new governance of the health. It is urgent to make relevant choices, to identify territories and some ambitious projects where the France have any legitimacy to be world class. Regardless of the projects that will be born after the States General of the industry, the world of health, they must never lose sight of the four actors are: the potential patient, health professional, the industry that I represent in the Snitem (national Union of the medical technology industry) and, finally, the taxpayer to optimize the cost/benefit of the health report.